Literature DB >> 15933386

Type 2 diabetes is negatively associated with Alzheimer's disease neuropathology.

Michal Schnaider Beeri1, Jeremy M Silverman, Kenneth L Davis, Deborah Marin, Hillel Z Grossman, James Schmeidler, Dushyant P Purohit, Daniel P Perl, Michael Davidson, Richard C Mohs, Vahram Haroutunian.   

Abstract

BACKGROUND: In cross-sectional and longitudinal studies, type 2 diabetes has been positively associated with the risk of Alzheimer's disease (AD). The present descriptive study compared diabetic and nondiabetic subjects on the severity of neuritic plaques and neurofibrillary tangles (NFTs) in the cerebral cortex and in the hippocampus.
METHODS: The study included specimens from 385 consecutive autopsies of residents of a nursing home (15.8% diabetics). Mean age at death = 84 years [standard deviation (SD) = 10], 66% were female, Clinical Dementia Rating mean = 3.0 (SD = 1.6), and 32.5% had an APOE4 allele. Additional analyses limited the sample to 268 subjects (14.1% diabetics) without neuropathology other than AD.
RESULTS: Analyses of covariance controlling for age at death, dementia severity (Clinical Dementia Rating score), and APOE4 allele indicated that diabetics had significantly fewer neuritic plaques (p =.008) and NFTs (p =.047) in the cerebral cortex than did nondiabetics. In the hippocampus, diabetics had significantly lower plaque ratings than did nondiabetics (p =.019), but the lower ratings of NFTs did not achieve statistical significance (p =.082). In the entire sample, diabetics had significantly less AD-associated neuropathology in all four analyses.
CONCLUSIONS: These results raise the possibility that the varied associations observed between diabetes and AD may be specific to as yet ill-defined subgroups of dementia and diabetic patients or may be more characteristic of younger patients than of those who survive to a mean age of 84 years. Future studies are encouraged to examine a variety of other characteristics such as age that may interact with diabetes affecting the incidence of AD.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15933386      PMCID: PMC3163091          DOI: 10.1093/gerona/60.4.471

Source DB:  PubMed          Journal:  J Gerontol A Biol Sci Med Sci        ISSN: 1079-5006            Impact factor:   6.053


  41 in total

1.  APOE epsilon4 does not predict mortality, cognitive decline, or dementia in the oldest old.

Authors:  K Juva; A Verkkoniemi; P Viramo; T Polvikoski; K Kainulainen; K Kontula; R Sulkava
Journal:  Neurology       Date:  2000-01-25       Impact factor: 9.910

2.  Neuronal and glial advanced glycation end product [Nepsilon-(carboxymethyl)lysine]] in Alzheimer's disease brains.

Authors:  A Takeda; M Wakai; H Niwa; R Dei; M Yamamoto; M Li; Y Goto; T Yasuda; Y Nakagomi; M Watanabe; T Inagaki; Y Yasuda; T Miyata; G Sobue
Journal:  Acta Neuropathol       Date:  2001-01       Impact factor: 17.088

Review 3.  Intervening in atherogenesis: lessons from diabetes.

Authors:  H Vlassara
Journal:  Hosp Pract (1995)       Date:  2000-11-15

4.  Enhancement of memory in Alzheimer disease with insulin and somatostatin, but not glucose.

Authors:  S Craft; S Asthana; J W Newcomer; C W Wilkinson; I T Matos; L D Baker; M Cherrier; C Lofgreen; S Latendresse; A Petrova; S Plymate; M Raskind; K Grimwood; R C Veith
Journal:  Arch Gen Psychiatry       Date:  1999-12

5.  Neurofibrillary tangles in nondemented elderly subjects and mild Alzheimer disease.

Authors:  V Haroutunian; D P Purohit; D P Perl; D Marin; K Khan; M Lantz; K L Davis; R C Mohs
Journal:  Arch Neurol       Date:  1999-06

Review 6.  Genetic factors in the genesis of Alzheimer's disease.

Authors:  P H St George-Hyslop
Journal:  Ann N Y Acad Sci       Date:  2000       Impact factor: 5.691

7.  Cardiovascular risk factors and cognitive decline in middle-aged adults.

Authors:  D Knopman; L L Boland; T Mosley; G Howard; D Liao; M Szklo; P McGovern; A R Folsom
Journal:  Neurology       Date:  2001-01-09       Impact factor: 9.910

Review 8.  The blood-brain barrier and cerebrovascular pathology in Alzheimer's disease.

Authors:  R N Kalaria
Journal:  Ann N Y Acad Sci       Date:  1999       Impact factor: 5.691

Review 9.  Vascular risk factors for Alzheimer's disease: an epidemiologic perspective.

Authors:  M M Breteler
Journal:  Neurobiol Aging       Date:  2000 Mar-Apr       Impact factor: 4.673

10.  Elevated serum total and LDL cholesterol in very old patients with Alzheimer's disease.

Authors:  G Lesser; K Kandiah; L S Libow; A Likourezos; B Breuer; D Marin; R Mohs; V Haroutunian; R Neufeld
Journal:  Dement Geriatr Cogn Disord       Date:  2001 Mar-Apr       Impact factor: 2.959

View more
  78 in total

1.  Cognitive impairment in nondiabetic middle-aged and older adults is associated with insulin resistance.

Authors:  H Bruehl; V Sweat; J Hassenstab; V Polyakov; A Convit
Journal:  J Clin Exp Neuropsychol       Date:  2010-06       Impact factor: 2.475

Review 2.  Potential predictors of hippocampal atrophy in Alzheimer's disease.

Authors:  Vikas Dhikav; Kuljeet Anand
Journal:  Drugs Aging       Date:  2011-01-01       Impact factor: 3.923

Review 3.  Selected findings from the Religious Orders Study and Rush Memory and Aging Project.

Authors:  David A Bennett; Robert S Wilson; Zoe Arvanitakis; Patricia A Boyle; Leyla de Toledo-Morrell; Julie A Schneider
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

4.  Interaction Between Midlife Blood Glucose and APOE Genotype Predicts Later Alzheimer's Disease Pathology.

Authors:  Katherine J Bangen; Jayandra J Himali; Alexa S Beiser; Daniel A Nation; David J Libon; Caroline S Fox; Sudha Seshadri; Philip A Wolf; Ann C McKee; Rhoda Au; Lisa Delano-Wood
Journal:  J Alzheimers Dis       Date:  2016-07-06       Impact factor: 4.472

Review 5.  The Wnt signaling pathway: aging gracefully as a protectionist?

Authors:  Kenneth Maiese; Faqi Li; Zhao Zhong Chong; Yan Chen Shang
Journal:  Pharmacol Ther       Date:  2008-02-11       Impact factor: 12.310

Review 6.  Type 2 diabetes and cognitive impairment: contributions from neuroimaging.

Authors:  John P Ryan; David F Fine; Caterina Rosano
Journal:  J Geriatr Psychiatry Neurol       Date:  2014-01-05       Impact factor: 2.680

7.  Antidiabetic drug metformin (GlucophageR) increases biogenesis of Alzheimer's amyloid peptides via up-regulating BACE1 transcription.

Authors:  Yaomin Chen; Kun Zhou; Ruishan Wang; Yun Liu; Young-Don Kwak; Tao Ma; Robert C Thompson; Yongbo Zhao; Layton Smith; Laura Gasparini; Zhijun Luo; Huaxi Xu; Francesca-Fang Liao
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-23       Impact factor: 11.205

Review 8.  Neuropathology of type 2 diabetes: a short review on insulin-related mechanisms.

Authors:  Elizabeth Guerrero-Berroa; James Schmeidler; Michal Schnaider Beeri
Journal:  Eur Neuropsychopharmacol       Date:  2014-01-30       Impact factor: 4.600

9.  Diabetes, Hemoglobin A1C, and Regional Alzheimer Disease and Infarct Pathology.

Authors:  Jeremy J Pruzin; Julie A Schneider; Ana W Capuano; Sue E Leurgans; Lisa L Barnes; Rexford S Ahima; Steven E Arnold; David A Bennett; Zoe Arvanitakis
Journal:  Alzheimer Dis Assoc Disord       Date:  2017 Jan-Mar       Impact factor: 2.703

Review 10.  The neuropathology of obesity: insights from human disease.

Authors:  Edward B Lee; Mark P Mattson
Journal:  Acta Neuropathol       Date:  2013-10-06       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.